Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
Zepbound (Tirzepatide)
General Medication Fact Sheet for Zepbound
| Field | Information |
|---|---|
| Medication Name | Zepbound |
| Generic Name | Tirzepatide |
| Purpose | Treatment of obesity and overweight in adults with at least one weight-related condition. |
| Mechanism of Action | Dual GIP and GLP-1 receptor agonist, improving glycemic control and reducing appetite. |
| Dosage Forms | Subcutaneous injection (pre-filled pen) |
| Available Strengths | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg |
| Dosage Frequency | Once weekly |
| Common Side Effects | Nausea, diarrhea, vomiting, constipation, abdominal pain |
| Serious Side Effects | Pancreatitis, gallbladder problems, kidney problems, severe allergic reactions. |
| Drug Interactions | Insulin secretagogues (e.g., sulfonylureas), insulin |
| Important Notes | Use with a reduced-calorie diet and increased physical activity. Consult a doctor if you have a history of pancreatitis. |
| Storage | Store refrigerated at 36°F to 46°F (2°C to 8°C). Do not freeze. Protect from light. |
| Missed Dose | Administer as soon as possible within 4 days of the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. |
| Alternatives | Mounjaro (tirzepatide), Ozempic (semaglutide), Wegovy (semaglutide), Saxenda (liraglutide) |
Zepbound Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Mounjaro (tirzepatide) | Dual GIP and GLP-1 receptor agonist | Also contains tirzepatide, similar mechanism of action, primarily indicated for type 2 diabetes. |
| Ozempic (semaglutide) | GLP-1 receptor agonist | Indicated for type 2 diabetes; may also result in weight loss. |
| Wegovy (semaglutide) | GLP-1 receptor agonist | Also contains semaglutide but approved specifically for weight loss. |
| Saxenda (liraglutide) | GLP-1 receptor agonist | An older GLP-1 receptor agonist approved for weight loss. |
Zepbound Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Nausea | Pancreatitis |
| Diarrhea | Gallbladder problems (e.g., gallstones, cholecystitis) |
| Vomiting | Kidney problems |
| Constipation | Severe allergic reactions (e.g., anaphylaxis, angioedema) |
| Abdominal pain | Increased risk of medullary thyroid carcinoma (based on animal studies, risk in humans unknown) |
Zepbound Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Obesity/Overweight | 2.5 mg once weekly | May be increased by 2.5 mg every 4 weeks until a maintenance dose of 5 mg, 10 mg, or 15 mg once weekly is reached. | Administer subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites. Use with diet and exercise. |




